<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563770</url>
  </required_header>
  <id_info>
    <org_study_id>QPHT-35</org_study_id>
    <nct_id>NCT01563770</nct_id>
  </id_info>
  <brief_title>Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen)</brief_title>
  <official_title>A Double Blind, Randomized Placebo-controlled Cross-over Study on the Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen) in Patients With Hypertension and Hyperlipidemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Extracts of the plant Salvia miltiorrhiza (Danshen) have been used as traditional
      Chinese medicine in the treatment of cardiovascular diseases, such as angina pectoris and
      myocardial infarction. Several preclinical studies point towards promising effects of Danshen
      on risk factors of atherosclerotic cardiovascular diseases, such as hyperlipidemia and
      hypertension.

      Objective: Our primary objective is to determine the effect of Salvia miltiorrhiza extract
      (Danshen) on hyperlipidemia. Secondary objective is to investigate the effect of Danshen on
      hypertension. Further objectives are to determine its effect on endothelial function,
      oxidative stress, inflammation, hemostasis and hemorheology, and on insulin sensitivity.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperlipidemia</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
    <description>Blood tests: lipids, in particular LDL-cholesterol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma markers of oxidative stress</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular inflammation and inflammatory activation of adipose tissue</measure>
    <time_frame>after 4 weeks of treatment with danshen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostasis and hemorheological parameters</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Hypertension</condition>
  <condition>Vasodilation</condition>
  <condition>Oxidative Stress</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Salvia miltiorrhiza extract (Danshen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>p.o. Salvia miltiorrhiza extract, 1.5 g twice daily for four consecutive weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>p.o. placebo, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Salvia miltiorrhiza extract</intervention_name>
    <description>3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks</description>
    <arm_group_label>Salvia miltiorrhiza extract (Danshen)</arm_group_label>
    <other_name>Danshen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 placebo capsules, twice daily for four consecutive weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 40-70

          -  Women:

               -  postmenopausal, or

               -  use of contraceptive pill

          -  Hyperlipidemia:

               -  elevated level of triglycerides: &gt; 1.7 mmol/L, or

               -  elevated level of LDL-cholesterol: &gt; 3.5 mmol/L

          -  Hypertension:

               -  systolic pressure &gt; 140 mm Hg, or

               -  diastolic pressure &gt; 90 mm Hg

          -  Signed informed consent

        Exclusion Criteria:

          -  Alcohol or drug abuse

          -  History of cardiovascular disease (myocard infarct, angina pectoris, CVA)

          -  Diabetes mellitus, when treated with insulin

          -  Pregnancy

          -  Hyperlipidemia which needs conventional treatment

               -  elevated level of triglycerides: &gt; 8 mmol/L

               -  elevated level of LDL-cholesterol: &gt; 5 mmol/L

          -  Hypertension which needs conventional treatment:

               -  systolic pressure &gt; 180 mm Hg

               -  diastolic pressure &gt; 110 mm Hg

          -  Clinically significant liver disease (3 times the upper normal limit of ALAT,ASAT)

          -  Clinically significant anemia (male Hb &lt; 6,9 mmol/L, female &lt; 6,25 mmol/L)

          -  Renal disease defined as MDRD &lt; 60 ml/min/1.73m2

          -  Participation to any drug-investigation during the previous 90 days

          -  Use of any herbal product during the previous 30 days

          -  Concomitant (chronic) use of:

        Medicinal products:

          -  ACE-inhibitors, including a.o. captopril, enalapril, ramipril

          -  AT1-antagonists, including a.o. losartan, valsartan, irbesartan

          -  Statins, including a.o. simvastatin, rosuvastatin

          -  Anticoagulant drugs, including a.o. aspirin

          -  Calciumantagonists (including a.o. amlodipine, nifedipine, verapamil)

          -  Use of more than 1 antihypertensive drug

          -  High-dose antihypertensive medication (above defined daily dose)

          -  Drugs which are exclusively metabolised by CYP3A4 (Flockhart DA; P450 drug interaction
             table, including a.o. erythromycin, midazolam, cyclosporine, HIV antivirals)

        Food products:

          -  (Antioxidant) vitamin supplements

          -  Other herbs, including a.o. St John's wort

          -  Grapefruit juice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Rongen, MD, PhD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pauline Breedveld, PhD</last_name>
    <phone>+31243614597</phone>
    <email>p.breedveld@pharmtox.umcn.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pleun van Poppel, MD</last_name>
    <phone>+31243667211</phone>
    <email>p.vanpoppel@aig.umcn.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Breedveld, PhD</last_name>
      <phone>+31-243614597</phone>
      <email>p.breedveld@pharmtox.umcn.nl</email>
    </contact>
    <contact_backup>
      <last_name>Pleun van Poppel, MD</last_name>
      <phone>+31-243667211</phone>
      <email>p.vanpoppel@aig.umcn.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Gerard Rongen, MD, PhD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cees J. Tack, MD, PhD, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Vasodilation</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>Hemorheology</keyword>
  <keyword>Cardiovascular diseases</keyword>
  <keyword>Cardiovascular agents</keyword>
  <keyword>Salvia miltiorrhiza</keyword>
  <keyword>Danshen</keyword>
  <keyword>Danshen root extract</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Therapeutic Uses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

